• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Swan Joseph increased direct ownership by 5,079% to 51,793 units (SEC Form 5)

    8/2/24 6:10:16 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IXHL alert in real time by email
    SEC FORM 5 SEC Form 5
    FORM 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0362
    Estimated average burden
    hours per response: 1.0
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Form 3 Holdings Reported.
    X
    Form 4 Transactions Reported.
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Swan Joseph

    (Last) (First) (Middle)
    105 / 8 CENTURY CIRCUIT

    (Street)
    NORWEST, NEW SOUTH WALES C3 2153

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Incannex Healthcare Inc. [ IXHL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CFO, Treasurer and Secretary
    3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
    06/30/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Amount (A) or (D) Price
    Restricted Shares of Common Stock 05/06/2024(1) A4(2) 50,793 A $0 51,793 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Award of restricted shares of which 16,931 restricted shares vested on June 30, 2024, 16,931 restricted shares will vest on June 30, 2025, and 16,931 restricted shares will vest on June 30, 2026, provided the Reporting Person is still employed on each vesting date.
    2. This Form 5 reports the award of 50,793 restricted shares by the Reporting Person pursuant to the Company's Equity Incentive Plan occurred on May 6, 2024.
    /s/ Joseph Swan 08/02/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IXHL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IXHL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IXHL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Valentine Troy was granted 11,302,608 shares, increasing direct ownership by 1,616% to 12,001,858 units (SEC Form 4)

    4 - Incannex Healthcare Inc. (0001873875) (Issuer)

    11/14/25 6:18:24 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Clark Robert was granted 1,686,956 shares, increasing direct ownership by 1,687% to 1,786,956 units (SEC Form 4)

    4 - Incannex Healthcare Inc. (0001873875) (Issuer)

    11/14/25 6:17:03 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Widdows Peter was granted 1,686,956 shares, increasing direct ownership by 623% to 1,957,803 units (SEC Form 4)

    4 - Incannex Healthcare Inc. (0001873875) (Issuer)

    11/14/25 6:15:28 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IXHL
    SEC Filings

    View All

    Incannex Healthcare Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Incannex Healthcare Inc. (0001873875) (Filer)

    1/15/26 9:57:26 PM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Incannex Healthcare Inc. (0001873875) (Filer)

    1/15/26 7:30:52 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Incannex Healthcare Inc. (0001873875) (Filer)

    1/14/26 7:30:53 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IXHL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards

    MELBOURNE, Australia and NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has been honored with the Research and Development Award in the Respiratory Disorders category of the 2025 Clinical Trials Arena Excellence Awards for its work advancing IHL-42X, the Company's oral fixed-dose combination product candidate for the treatment of obstructive sleep apnea (OSA). The Clinical Trials Arena Excellence Awards is an independent recognition program powered by GlobalData's business intelligence, in which researchers, journalists, and artificial intell

    1/15/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026

    MELBOURNE, Australia and NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, provides a 2025 corporate year-in-review and outlook for 2026, highlighting substantial clinical, regulatory and financial progress that positions the Company for continued execution. "The year 2025 was a defining one for Incannex," stated Joel Latham, Incannex Healthcare Chief Executive Officer. "We delivered two independent, positive Phase 2 clinical readouts across distinct CNS programs, achieved FDA Fast Track designation for our lead OSA candidate, and materially strengthened our balance sh

    1/14/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)

    MELBOURNE, Australia and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IHL-42X, the Company's oral fixed-dose combination product candidate for the treatment of obstructive sleep apnea (OSA). The Fast Track designation was supported by promising safety, efficacy, and pharmacokinetic results from the three clinical trials completed to date within the IHL-42X development program. These include the Company's successful Phase 2 "RePOSA" study demonstrating statistically si

    12/3/25 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IXHL
    Leadership Updates

    Live Leadership Updates

    View All

    Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

    NEW YORK and MELBOURNE, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Charlene E. Gamaldo, M.D. to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. Incannex Chief Medical Officer Dr. Lou Barbato commented:"We are fortunate to welcome Dr. Gamaldo to the Incannex Clinical Advisory Board. Her leadership across neurology, psychiatry, and public health, combined with a distinguished track record in sleep medicine, brings tremendous value to our obstructive sleep apnea prog

    7/25/25 7:30:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

    NEW YORK and MELBOURNE, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Douglas B. Kirsch, M.D., FAAN, FAASM to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. "We are honored to welcome Dr. Kirsch to the IHL-42X Clinical Advisory Board," stated Dr. Lou Barbato, Incannex Chief Medical Officer. "His extensive clinical experience and leadership within the sleep medicine community will be instrumental as we advance IHL-42X through late-stage development. With his additi

    6/24/25 7:30:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

    NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced the recent appointment of four distinguished experts to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board: Scott A. Sands, Ph.D., Associate Professor of Medicine at Harvard Medical School and Director of the Sleep Apnea Translational Physiology Group in the Division of Sleep and Circadian Disorders at Brigham and Women's Hospital.Ali Azarbarzin, Ph.D., Associate Professor of Medicine at Harvard Medical School and a lead

    6/3/25 7:30:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IXHL
    Financials

    Live finance-specific insights

    View All

    Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

    MELBOURNE, Australia, July 27, 2022 /PRNewswire/ -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ:IXHL), ('Incannex' or the 'Company'), is pleased to provide its quarterly activities report and appendix 4C for the period ended 30 June 2022. Incannex is undertaking a multitude of U.S. Food and Drug Administration ('FDA') programs for cannabinoid pharmaceutical products and psychedelic medicine therapies administered by health professionals. Cannabinoid IHL-42X: positive phase 2a clinical trial results in patients with obstructive sleep apnoea In June 2022, Incannex announced positive results from full analysis of its phase 2 clinical trial o

    7/27/22 7:55:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quarterly Activities Report and Appendix 4C Cash Flow Statement

    Highlights: Positive phase 2a clinical trial results for IHL-42X with 60% of trial participants experiencing at least a 55% reduction in the Apnoea Hypopnea Index ('AHI') 20% of IHL-42X clinical trial participants experienced a reduction in AHI of greater than 80% completes comprehensive in vivo study on the neuroprotective capability of IHL-216A with results being analysed to be released within 2-3 weeks treatment commences in the phase 2a clinical trial to assess psilocybin and specialised psychotherapy for the treatment of generalised anxiety disorder initiates a second clinical psychedelic therapy program in a leading-edge academic field of virtual reality (VR) exposure response therapy

    4/28/22 7:55:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care